News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Dr. Reddy’s Laboratories, Inc. Announces the Launch of Zafirlukast Tablets
November 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Zafirlukast tablets (10 mg and 20 mg), a bioequivalent generic version of Accolate® in the US market.
Twitter
LinkedIn
Facebook
Email
Print
Asia
MORE ON THIS TOPIC
Collaboration
Alphabet Subsidiary Calico Colors In Up To $570M+ Aging Deal With China’s Mabwell
June 27, 2025
·
2 min read
·
Tristan Manalac
Government
FDA Freezes Trials Shipping Cells to China, ‘Other Hostile Countries’
June 20, 2025
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal
June 16, 2025
·
1 min read
·
Dan Samorodnitsky
Autoimmune disease
Cullinan Bets $700M+ in Back-Heavy China Deal for Autoimmune T Cell Engager
June 5, 2025
·
2 min read
·
Tristan Manalac
